Agilent

Tuesday, February 8th, 2022 at 9am EST | 3pm CET | 2pm GMT and 2pm EST | 11am PST | 7pm GMT Approaches and lessons learned on developing an HPLC methodology to cover a complex and broad range of polar analytes: the complete cellular pool of nucleosides and nucleotides plus our drug candidates and associated prodrugs. The utility of PEEK-lined columns and newer HILIC-Z column phases is highlighted in this anecdote of HPLC methodology development.

This application note describes multi-attribute analysis of monoclonal antibodies. The analyzer combines multidimensional chromatographic multimethod analysis options.

The 1290 Infinity II Bio LC including High-Speed Pump, with its iron‑free flow path, is optimally suited for the conditions used in biochromatography.

This paper describes the requirements for electronic records and electronic signatures for regulated pharmaceutical organizations.

Analysis of antibody drug conjugates using hydrophobic interaction chromatography with the Agilent 1290 Infinity II Bio LC System

The Agilent Bio-Monolith rProtein A (recombinant protein A) analytical column is the latest addition to the Bio-Monolith and affinity chromatography family.

Superior resolution in size exclusion chromatography (SEC) protein separation made possible by the Agilent 1290 Infinity II Bio LC System.

The Agilent 1290 Infinity II Bio LC System is the new platform for UV and MS-based primary structure and PTMs analysis of mAbs.

This study demonstrates how to increase sample throughput for glycan characterization workflows using the Agilent AssayMAP Bravo liquid handling platform.

Peptide-mapping analysis shows excellent performance and high method compatibility compared to the Agilent 1290 Infinity II LC System.

Tuesday, January, 11th, 2022 at 9am EST | 3pm CET | 2pm GMT Tuesday, January, 11th, 2022 at 2pm EST | 11am PST | 7pm GMToin us in our expert discussion of Rapid Analysis of mRNA 5’ Capping and Poly-A Tailing with High-Resolution LC-MS. See how mRNA capping can be analyzed by LC-MS within 75 minutes!

This application demonstrates excellent performance in method development for the analysis of raw materials for oligonucleotide synthesis using a biocompatible UHPLC.

This application note describes the drug-to-antibody determination of brentuximab vedotin using a ternary gradient with isopropanol as third channel organic modifier.

*Europe Broadcast: Tuesday, May 18, 2021 9am EDT | 2pm BST | 3pm CEST and US Broadcast: Tuesday, May 18, 2021 2pm EDT | 1pm CDT | 11am PDT* Biopharmaceutical companies are transitioning from “quality-by-testing” philosophy to “quality-by-design” paradigms, and establishing QbD-based PAT tools to increase product and process understanding. Due to the deficit of analytical methods to support QbD-driven continuous bioprocessing, biopharmaceutical companies are actively developing PAT tools to comply with QbD regulations. *On Demand Until May 18, 2022*

*Tuesday, May 11, 2021 at 9am EDT | 2pm BST | 3pm CEST, Tuesday, May 11, 2021 at 2pm EDT | 1pm CDT | 11am PDT* Adeno-associated viruses (AAVs) are an important tool enabling the delivery of next-generation gene therapies. *Available On Demand Until May 11, 2022*